Innovative contracts continue to gain traction and improve quality of care

Innovative contracts can help bring more value to patients and the health care system. These types of payment arrangements can include:
Read More
Growth in innovative, value-based contracts holds promise for the health system and for patients

The extraordinary financial pressure COVID-19 is creating for the U.S. economy underscores the need for a renewed push toward a more value-driven health care system that prioritizes patient access...
Read More
Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country

A new analysis from Xcenda applied the Institute for Clinical and Economic Review’s (ICER) value assessments to state Medicaid programs in California, Massachusetts, Maryland, Nevada and New York....
Read More
5 Ways to improve ICER’s value assessment framework

The Institute for Clinical and Economic Review’s (ICER) recently made a call for suggestions and feedback on how to improve its value assessment framework and methods. We are a strong supporter of...
Read More
Assessing value top of mind at ISPOR 2019

As we move toward a value-driven health care system, the focus should be on outcomes that matter most to patients, such as how medicines make patients feel, whether they can return to work or how...
Read More
Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care

Tomorrow, October 3, PhRMA will convene health care leaders for a discussion on how we can move our health care system toward one focused on value rather than volume, ensuring patients can access the...
Read More
New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers

A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) cost-effective analyses (CEAs) will not be...
Read More
Guest post: Developing new payment models to ensure patients have access to high-investment therapies

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Number of value-based contracts continues to rise

The list of publicly announced value-based contracts (VBCs) – also called results-based contracts – between biopharmaceutical companies and health plans continued to grow over the last quarter – from...
Read More